1-4 of 4
William S Dalton, M.D., Ph.D
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of Bortezomib(Bz), Pegylated Doxorubicin(DOX) and Dexamethasone(dex); ( VDD) with Escalating Doses of Cyclophosphamide(Cy) in Patients with Newly Diagnosed Myeloma.

Melissa Alsina, MD, Rachid Baz, MD, Jose L Ochoa, MD, Jyotishankar Raychaudhuri, Kara Kosakowski, Michelle Mintz, Kendra Anderson, William S Dalton, M.D., Ph.D, Daniel Sullivan
Journal: Blood
Blood (2009) 114 (22): 617.
https://doi.org/10.1182/blood.V114.22.617.617
Published: 2009
Journal Articles

β1 Integrin Adhesion Enhances IL-6 Mediated STAT3 Signaling in Multiple Myeloma Cells: Implications for Microenvironment Influence on Tumor Cell Survival and Proliferation.

Kenneth H Shain, M.D., Ph.D., Danielle Yarde, Mark Mead, Ph.D., Lori Hazlehurst, Ph.D., William S Dalton, M.D., Ph.D
Journal: Blood
Blood (2008) 112 (11): 1706.
https://doi.org/10.1182/blood.V112.11.1706.1706
Published: 2008
Journal Articles

NF-kB as a Regulator of FA/BRCA Gene Expression in Multiple Myeloma.

Vasco A. Oliveira, PhD, Linda Mathews, B.Sc., Danielle Yarde, B.Sc, Xingyu Wang, Ph.D., David Boulware, M.Sc., Lori A. Hazlehurst, Ph.D., Dung-Tsa Chen, Ph.D., Amer Beg, Ph.D., William S. Dalton, M.D., Ph.D.
Journal: Blood
Blood (2007) 110 (11): 3508.
https://doi.org/10.1182/blood.V110.11.3508.3508
Published: 2007
Journal Articles

Bortezomib-Induced Reversal of CAM-DR Phenotype in Myeloma Is Associated with AKT and ERK1/2 Signaling.

Ramadevi Nimmanapalli, Ph.D, Lori Hazlehurst, Ph.D, Steven Enkemann, Ph.D, Melissa Alsina, M.D., William S. Dalton, M.D., Ph.D
Journal: Blood
Blood (2004) 104 (11): 3357.
https://doi.org/10.1182/blood.V104.11.3357.3357
Published: 2004